Translational medicine lessons from flurizan's failure in alzheimer's disease (AD) trial: Implication for future drug discovery and development for AD

Clinical and Translational Science

Volumn 2, Issue 3, 2009, Pages 242-247

  Wan, Hong I ^a   Jacobsen, J Steve ^b   Rutkowski, J Lynn ^c   Feuerstein, Giora Z ^a  

^a Department of Clinical Translational Medicine ^*  (United States)

^b PFIZER INC   (United States)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; GSI 953; HOMOTAURINE; N2 [2 (3,5 DIFLUOROPHENYL) 2 HYDROXYACETYL] N1 (6,7 DIHYDRO 5 METHYL 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL)ALANINAMIDE; PLACEBO; PRESENILIN; TARENFLURBIL; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; BIOSYNTHESIS; CLINICAL DECISION MAKING; CLINICAL RESEARCH; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUSTRY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; DRUG TREATMENT FAILURE; GLUCOSE METABOLISM; HUMAN; IC 50; MAXIMUM PLASMA CONCENTRATION; NEUROFIBRILLARY TANGLE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ASSEMBLY; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT RESPONSE;

ALZHEIMER DISEASE; ANIMALS; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; DRUG DISCOVERY; FLURBIPROFEN; HUMANS; PATIENT SELECTION; REPRODUCIBILITY OF RESULTS; TRANSLATIONAL RESEARCH; TREATMENT FAILURE;

EID: 77953422164     PISSN: 17528054     EISSN: 17528062     Source Type: Journal    
DOI: 10.1111/j.1752-8062.2009.00121.x     Document Type: Article

References (34)

1. Feuerstein GZ. The role of translational medicine and biomarkers research in drug discovery and development. Am Drug Discov. 2007; 2: 23-28.
2. Feuerstein GZ, Dormer C, Walsh FS, Hurko O, Rutkowski JL. Translational medicine perspectives in drug discovery and development part III: disease biomarkers, disease modifying biomarkers, disease labeling biomarkers and surrogate biomarkers. Am Drug Discov. 2008; 2(4): 36-41.
3. Feuerstein GZ, Ruffolo RR, Jr, Stiles G, Walsh FS, Rutkowski JL. Translational medicine perspectives of biomarkers in drug discovery and development: Part I target selection and validation-biomarkers take center stape. Am Drun Discov. 2007: 2(5): 36-43.
4. Feuerstein GZ, Dormer C, Ruffolo RR, Jr, Rutkowski JL, Walsh FS, Hurko O. Translational medicine perspectives in drug discovery and development part II: Target compounT interaction: the vastly neglected biomarkers contributing to early clinical development failure. Am Drug Discov. 2008; 3(2): 48-54.
5. Selkoe DJ. Alzheimer's disease: Genes, proteins, and therapy. Physioi Rev. 2001; 81(2): 741-766.
6. Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH, Yu CE, Jondro PD, Schmidt SD, Wang K. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science. 1995; 269(5226): 973-977.
7. Sherrington R, Rogaev El, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature. 1995; 375(6534): 754-760.
8. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM. Clinical effects of Abeta immunization (AN 1792) in patients with AD in an interrupted trial. Neuroiogy. 2005; 64(9): 1553-1562.
9. Gilman S. Clinical trials of bapineuzumab A-beta-amyloid-targeted immunotherapy in patients with mild-to-moderate Alzheimers disease. Paper presented at the International Conference on Alzheimer's Disease and Related Disorders Meeting, July 27-31, 2008. Chicago, IL, USA.
10. Fripp J, Bourgeat P, Acosta O, Raniga P, Modat M, Pike KE, Jones G, O'Keefe G, Masters CL, Ames D, Ellis KA, Muruff P, Currie J, Villemagne VL, Rowe CC, Salvado O, Ourselin S. Appearance modeling of 11C PiB PET images: Characterizing amyloid deposition in Alzheimer's disease, mild cognitive impairment and healthy aging. Neuroimage. 2008; 43: 430-439.
11. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, Kang DE, Marquez-Sterling N, Golde TE, Koo EH. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature. 2001; 414(6860): 212-216.
12. Kukar T, Golde TE. Possible mechanisms of action of NSAIDs and related compounds that modulate gamma-secretase cleavage. Curr Top Med Chem. 2008; 8(1): 47-53.
13. Lleo A, Berezovska O, Herl L, Raju S, Deng A, Bacskai BJ, Frosch MP, Irizany M, Hyman BT. Nonsteroidal anti-inflammatory drugs lower Abeta42 and change presenilin 1 conformation. Nat Med. 2004; 10(10): 1065-1066.
14. Beher D, Clarke EE, Wrigley JD, Martin AC, Nadin A, Churcher I, Shearman MS. Selected nonsteroidal anti-inflammatory drugs and their derivatives target gamma-secretase at a novel site. Evidence for an allosteric mechanism. J Biol Chem. 2004; 279(42): 43419-43426.
15. Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLendon DC, Ozols VV, Jessing KW, Zavitz KH, Koo EH, Golde TE. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Gin Invest. 2003; 112(3): 440-449.
16. Morihara T, Chu T, Ubeda O, Beech W, Cole GM. Selective inhibition of Abeta42 production byNSAIDR-enantiomers. J Neurochem. 2002; 83(4): 1009-1012.
17. Martone RL, Zhou H, Atchison K, Comery TA, Xu J, Huang X, Gong X, Jin M, Kreft A, Harrison B. GSI-953 (begacestat): A novel, selective thiophene sulfonamide inhibitor of APP gamma-secretase for the treatment of Alzheimer's disease. Manuscript in preparation. 2009.
18. Lanz TA, Karmilowicz MJ, Wood KM, Pozdnyakov N, Du P, Piotrowski MA, Brown TM, Nolan CE, Richter KE, Finley JE, Fei Q, Ebbinghaus CF, Chen YL, Spracklin DK, Tate B, Geoghegan KF, Lau LF, Auperin DD, Schachter JB. Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139. J Pharmacol Exp Ther. 2006; 319(2): 924-933.
19. Roberds SL, Anderson J, Basi G, Bienkowski MJ, Branstetter DG, Chen KS, Freedman SB, Frigon NL, Games D, Hu K, Johnson-Wood K, Kappenman KE, Kawabe TT, Kola I, Kuehn R, Lee M, Liu W, Motter R, Nicols NF, Power M, Robertson DW, Schenk D, Schoor M, Shopp GM, Shuch ME, Sinha S, Svensson KA, Tatsuno G, Tintrup H, Wijsman J, Wright S, McConlogue L. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: Implications for Alzheimer's disease therapeutics. Hum Mol Genet. 2001; 10(12): 1317-1324.
20. McConlogue L, Buttini M, Anderson JP, Brigham EF, Chen KS, Freedman SB, Games D, Johnson-Wood K, Lee M, Zeller M, Liu W, Motter R, Sinha S. Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APPtransgenic mice. J Biol Chem. 2007; 282(36): 26326-26334.
21. Kukar T, Prescott S, Eriksen JL, Holloway V, Murphy MP, Koo EH, Golde TE, Nicolle MM. Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neurosci. 2007; 8: 54.
22. Lanz TA, Fici GJ, Merchant KM. Lack of specific amyloid-beta(1-42) suppression by nonsteroidal anti-inflammatory drugs in young, plaque-free Tg2576 mice and in guinea pig neuronal cultures. J Pharmacol Exp Ther. 2005; 312(1): 399-406.
23. Murray ED, Quiggle D, Gibson K, Leipod D, Loughman B, Wechter W. Phase I single-dose pharmakinetics and lack of enantiomeric byconversion of E-7869 (R-flurbiprofen). Gin Pharmacol Ther. 2000; 67(2): 103.
24. Galasko DR, Graff-Radford N, May S, Hendrix S, Cottrell BA, Sagi SA, Mather G, Laughlin M, Zavitz KH, Swabb E, Golde TE, Murphy MP, Koo EH. Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals. Alzheimer Dis Assoc Disord. 2007; 21(4): 292-299.
25. Bateman RJ, Wen G, Morris JC, Holtzman DM. Fluctuations of CSF amyloid-beta levels: Implications for a diagnostic and therapeutic biomarker. Neurology. 2007; 68(9): 666-669.
26. Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med. 2006; 12(7): 856-861.
27. Siemers ER, Quinn JF, Kaye J, Farlow MR, Porsteinsson A, Tariot P, Zoulnouni P, Galvin JE, Holtzman DM, Knopman DS, Satterwhite J, Gonzales C, Dean RA, May PC. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology. 2006; 66(4): 602-604.
28. Wan HI, Bard J, Martone RL, Raje S, Forlow S, Balliet C, Pastore A, Burczynski ME, Atchison K, Zhou H, Mayer S, Adkins K, Gruver M, Rosen B, Harrison B, Magolda R, Reinhart P, Pangalos M, Kreft A, Jacobsen S, Silver P, Paul J, Frick G. GSI-953, a potent and selective gamma-secretase inhibitor, modulates Abeta peptides in mice and humans: translating the PK/PD biomarker relationships in different biological compartments between rodent and human. Paper presented at the ICAD, July 27-31, 2008, Chicago, IL
29. Jack CR, Jr, Petersen RC, Xu Y, O'Brien PC, Smith GE, Ivnik RJ, Boeve BF, Tangalos EG, Kokmen E. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology. 2000; 55(4): 484-489.
30. Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM. Longitudinal PET evaluation of cerebral metabolic decline in dementia: A potential outcome measure in Alzheimer's disease treatment studies. Am J Psychiatry. 2002; 159(5): 738-745.
31. Mosconi L, Tsui WH, De Santi S, Li J, Rusinek H, Convit A, Li Y, Boppana M, de Leon MJ. Reduced hippocampal metabolism in MCI and AD: Automated FDG-PET image analysis. Neurology. 2005; 64(11): 1860-1867
32. Wilcock GK, Black SE, Hendrix SB, Zavitz KH, Swabb EA, Laughlin MA. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: A randomised phase II trial. Lancet Neurol. 2008; 7(6): 483-493.
33. Green RCS, LS, Zavitz KH, Amato DA, Beelen AP, Swabb EA. Safety and efficacy of tarenflurbil in subjects with mild Alzheimer's disease: results from an 18-month multicenter phase 3 trial. Paper presented at the International Conference on Alzheimer's Disease and Related Disorders Meeting, July 27-31, 2008, Chicago, IL, USA.
34. Green RC, Schneider LS, Zavitz KH, Amato DA, Beelen AP, Swabb EA. safety and efficacy of tarenflurbil in subjects with mild Alzheimer's disease: results from an 18-month multicenter phase 3 trial. Paper presented at the ICAD, July 27-31, 2008, Chicago, IL, USA.